Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Jérôme Alexandre1, Marie-Aude Le Frère-Belda2, Antoine Angelergues3

  • 1Service d'oncologie médicale, AP-HP-centre université de Paris cité, site Cochin, 123 boulevard de Port-Royal, 75014 Paris, France.

Bulletin Du Cancer
|August 12, 2023
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Baseline value and longitudinal kinetics of circulating nucleosomes during neo-adjuvant chemotherapy in newly diagnosed ovarian cancer: Results from a GINECO/GINEGEPS study of the randomized phase II CHIVA trial.

Translational oncology·2026
Same author

Avelumab Plus Methotrexate for Gestational Trophoblastic Tumors: The TROPHAMET Phase 1/2 Nonrandomized Clinical Trial.

JAMA oncology·2026
Same author

Technical recommendations from a large-scale French Delphi consensus: A step toward European harmonization of ctDNA analysis.

European journal of cancer (Oxford, England : 1990)·2026
Same author

Efficacy of buparlisib according to PIK3CA mutation status in recurrent or metastatic head and neck squamous cell carcinoma: A multicenter phase II trial.

Oral oncology·2026
Same author

Changes in Cyclin E1 expression and CCNE1 amplification in high-grade ovarian carcinomas post-PARP inhibitor exposure.

British journal of cancer·2026
Same author

Prevalence of the Predisposing Gene MBD4 for Uveal Melanoma.

JAMA ophthalmology·2026
This summary is machine-generated.

Updated guidelines for advanced or relapsing endometrial cancer management now include new treatments improving patient survival. Treatment choice depends on tumor characteristics, with immunotherapy and targeted therapies offering new options.

Area of Science:

  • Gynecologic Oncology
  • Medical Oncology
  • Clinical Practice Guidelines

Context:

  • The management of advanced or relapsing endometrial cancer has evolved since the 2020 recommendations.
  • New therapeutic options have demonstrated improved life expectancy for patients.
  • This necessitates an update to clinical practice guidelines.

Purpose:

  • To provide updated clinical practice recommendations for the management of advanced/relapsing endometrial cancer.
  • To incorporate recent advancements in treatment options.
  • To guide clinicians in selecting appropriate therapies based on tumor characteristics.

Summary:

  • First-line treatment selection involves chemotherapy (carboplatin/paclitaxel) or hormone therapy (progestin), guided by tumor features (histology, grade, hormone receptor status, progression rate).
Keywords:
ChemotherapyChimiothérapieHormone therapyHormonothérapieLenvatinibMMR statusPembrolizumabStatut MMR

Related Experiment Videos

  • For dMMR tumors, immunotherapy in clinical trials is an option.
  • Post-first-line standard treatment is pembrolizumab plus lenvatinib, requiring close monitoring for toxicity.
  • Chemotherapy remains an option for salvage or specific scenarios (e.g., pMMR tumors with long disease-free interval).

    • Impact:

    • These updated recommendations aim to optimize treatment strategies for advanced/relapsing endometrial cancer.
    • Incorporating novel therapies like immunotherapy and targeted agents may further improve patient prognosis.
    • Ongoing clinical trials are crucial for continued advancements in personalized treatment approaches.